본문 바로가기
KERD
논문KCI 등재

Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience

최훈|김배환|이준혁|신현덕|신현성|이수진|김형준|이현석|현경희|권병운|김용현|송일한|이상석|한진형|강하얀
대한간학회 (The korean Association for the Study of the Liver)|2012.03|Clinical and Molecular Hepatology|제18권 제1호|pp. 48-88

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

TreatmentSurvivalHepatocellular carcinomaPrognosisTumor staging

초록

Background/Aims: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. Methods: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. Results: The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. Conclusions: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center. (Korean J Hepatol 2012;18:48-55)

Abstract

Background/Aims: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. Methods: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. Results: The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. Conclusions: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center. (Korean J Hepatol 2012;18:48-55)

참고문헌 (33)

  1. Song IH, "Current status of liver disease in Korea: hepatocellular carcinoma", Korean J Hepatol, 15(Suppl 6), pp.S50~S59 (2009)
  2. Annual report on the cause of death statistics 2005, "Korea National Statistical Office", Korea National Statistical Office, 6~15 (2006)
  3. Park JW, "National policy of early detection in hepatocellular carcinoma", Korean J Hepatol, 8(Suppl 3), pp.S16~S19 (2002)
  4. Kyu-Won Jung, "Cancer Survival in Korea 1993-2002: A Population-Based Study", Journal of Korean Medical Science, 22(S), pp.5~10 (2007), 대한의학회
  5. Capocaccia R, "Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century", Am J Gastroenterol, 102, pp.1661~1670 (2007)
  6. Toyoda H, "Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan", Cancer, 100, pp.2415~2421 (2004)
  7. 이재길, "The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection", Yonsei Medical Journal, 47(1), pp.105~112 (2006), 연세대학교의과대학
  8. Park YK, "Hepatic resection for hepatocellular carcinoma meeting milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis", Transplant Proc, 41, pp.1691~1697 (2009)
  9. 박상재, "간세포암종에 대한 연속된 간절제술 200예 예후인자 분석", 한국간담췌외과학회지, 10(1), pp.21~28 (2006), 한국간담췌외과학회
  10. Yon Mi Sung, "Long-term Results of Percutaneous Ethanol Injection for the Treatment of Hepatocellular Carcinoma in Korea", Korean Journal of Radiology, 7(3), pp.187~192 (2006), 대한영상의학회
  11. 조창민, "간세포암종의 치료에 있어 고주파 소작술과 수술적 절제의 비교", Clinical and Molecular Hepatology, 11(2005), pp.59~71 (2005), 대한간학회
  12. 이정현, "고주파열치료를 시행한 간세포암종 환자의 생존 예후 인자", 대한소화기학회지, 49(1), pp.17~23 (2007), 대한소화기학회
  13. Seong J, "A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea", Liver Int, 29, pp.147~152 (2009)
  14. 박경우, "간세포암종 환자의 5년 생존율 - 단일기관의 904명 코호트 연구", Clinical and Molecular Hepatology, 13(4), pp.530~542 (2007), 대한간학회
  15. Sobin LH, "TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer", Cancer, 80, pp.1803~1804 (1997)
  16. 한대훈, "10년간 단일 기관에서 간세포암의 수술적 절제의 경험 - 수술 후 장기 성적을 향상시킬 수 있는 전략", 한국간담췌외과학회지, 12(4), pp.245~253 (2008), 한국간담췌외과학회
  17. Lee JK, "Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization", Journal of Gastroenterology and Hepatology, 17(1), pp.52~58 (2002), Blackwell Publishing Inc.
  18. Park JW, "Practice guideline for diagnosis and treatment of hepatocellular carcinoma", Korean J Hepatol, 10, pp.88~98 (2004)
  19. Park KW, "Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area", J Gastroenterol Hepatol, 23, pp.467~473 (2008)
  20. Kanematsu T, "A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000", Surgery, 131(Suppl), pp.S153~S158 (2002)
  21. Lee CS, "Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma", Br J Surg, 83, pp.330~333 (1996)
  22. Llovet JM, "Updated treatment approach to hepatocellular carcinoma", J Gastroenterol, 40, pp.225~235 (2005)
  23. Park JH, "Chemoembolization of hepatocellular carcinoma: long-term survival and prognostic factors", J Korean Radiol Soc, 35, pp.315~323 (1996)
  24. Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
  25. Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
  26. Choi GH, "Outcome after curative resection for a huge (>or =10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification", Am J Surg, 198, pp.693~701 (2009)
  27. Wang HJ, "Surgical treatment of hepatocellular carcinoma", Korean J Gastroenterol, 45, pp.247~257 (2005)
  28. 조형원, "간세포암의 절제술 후 재발에 영향을 미치는 인자", 대한외과학회지, 69(6), pp.465~470 (2005), 대한외과학회
  29. 정인권, "단일 결절 간세포암종에서 고주파 열치료 후 예후에 영향을 미치는 인자", Clinical and Molecular Hepatology, 11(2005), pp.371~380 (2005), 대한간학회
  30. Lee HS, "The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study", Cancer, 79, pp.2087~2094 (1997)
  31. Kim KM, "Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion", J Gastroenterol Hepatol, 24, pp.806~814 (2009)
  32. Stuart KE, "Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival", Cancer, 77, pp.2217~2222 (1996)
  33. "A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators", Hepatology, 28, pp.751~755 (1998)

관련 논문AI추천

간세포암종 환자의 5년 생존율 - 단일기관의 904명 코호트 연구김성훈, 김창민, 김태현, 박경우, 박상재, 박중원, 박홍석, 신해림, 이우진, 최준일대한간학회 · Clinical and Molecular Hepatology2007 · 제13권 제4호Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma장영, 김윤준, 윤정환, 정진욱, Cho Eun Ju, Kim Hyo-Cheol, Lee Jeong-Hoon, Lee Yun Bin, Yu Su Jong거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제1호간세포암종 환자에서 병기, 간기능 및 치료법에 따른 3년 생존율 분석김대용, 김성훈, 김영일, 김창민, 박경우, 박상재, 박중원, 박홍석, 이우진, 조상형, 홍은경대한간학회 · Clinical and Molecular Hepatology2006 · 제12권 제2006호Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis강구정, 권영오, 김병석, 김영환, 박수영, 이유진, 이정민, 이창형, 장병국, 정우진, 최세명, 최왕용, 탁원영, 황재석, Anil Kumar Chauhan대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제1호Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma고광철, 곽금연, 김준영, 백승운, 백용한, 신동현, 신성욱, 안중현, 이준혁, 조성기, 조재원, 최규성, 최문석, Aldosri Meshal Saleh, Keumhee Chough Carriere대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제2호Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors손원, 고광철, 곽금연, 백승운, 백용한, 유병철, 이준혁, 조주연, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제5호

이 간행물의 다른 논문 (8건)

Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis최병길, 배시현, 천호종, 김혜림, 차정훈, 윤승규, 장정원, 연준모, 최종영, 우현영pp. 32-40Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients김윤정, 정우진, 조광범, 박경식, 김은수, 장병국, 황재석pp. 41-47Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test엄순호, 유호상, 임선영, 김지훈, 김혜숙, 김용식, 이홍식, 임형준, 김창하, 금보라, 서민호, 안형진, 서연석, 김창덕, 현종진pp. 56-82Co-expression patterns of Notch1, Snail, and p53 in grade III hepatocellular carcinoma with postoperative recurrence: a preliminary study김보현, 정구흥, Xiaoyuan Quan, 장선경, 최준정, 박영민, 장정원, 최기홍pp. 63-74High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B이희승, 윤세진, 최용혁, 서의금, 채희복, 박선미, 윤순만, 한정호pp. 75-83
원문 보기